J&J(US:JNJ) Businesswire·2025-10-14 10:20Core Viewpoint - Johnson & Johnson reported strong performance in Q3 2025, driven by a robust portfolio and progress in key therapeutic areas, indicating a new era of growth and innovation [1]. Overall Financial Results - The company does not provide GAAP financial measures on a forward-looking basis due to uncertainties related to legal proceedings and other factors [5]. Regional Sales Results - Specific regional sales results were not detailed in the provided content. Segment Sales Results Innovative Medicine - Worldwide operational sales grew by 5.3%, with net acquisitions and divestitures contributing positively by 1.6% due to CAPLYTA [3]. - Key growth drivers included DARZALEX, CARVYKTI, ERLEADA, and RYBREVANT/LAZCLUZE in Oncology, TREMFYA and SIMPONI/SIMPONI ARIA in Immunology, and SPRAVATO in Neuroscience [3]. - Growth was partially offset by a negative impact of approximately 1,070 basis points from STELARA in Immunology and IMBRUVICA in Oncology [3]. MedTech - Worldwide operational sales increased by 5.6%, with net acquisitions and divestitures negatively impacting growth by 0.1% [4]. - Growth was primarily driven by electrophysiology products, Abiomed, Shockwave in Cardiovascular, wound closure products in General Surgery, and Surgical Vision [4]. Notable Announcements in the Quarter - The company encourages reviewing its disclosures filed with the Securities and Exchange Commission for additional context [7]. Webcast Information - Johnson & Johnson will conduct a conference call with investors to discuss the earnings release, accessible via their website [8]. About Johnson & Johnson - The company emphasizes its commitment to healthcare innovation, aiming to prevent, treat, and cure complex diseases through its expertise in Innovative Medicine and MedTech [9].